GlassScriptPhysician profile
Tobie J Meyer
NPI 1316995715
$12,968.76
in general payments reported to CMS, 2019-2025
26 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $3,190 · 2023: $4,071 · 2024: $3,266 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,777 · Travel and Lodging: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,776.86 |
| Travel and Lodging | $1,113.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,904.80 | 2021-2024 | Senza |
| Abbott Laboratories | $2,156.54 | 2021-2025 | Proclaim |
| Boston Scientific Corporation | $1,638.06 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Relievant Medsystems, INC. | $1,296.16 | 2023 | Intracept |
| Saluda Medical Americas, INC. | $1,145.67 | 2022-2025 | Evoke Scs, Evoke |
| Medtronic, INC. | $1,005.40 | 2022-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Spr Therapeutics, INC | $851.08 | 2023-2025 | Sprint Pns System |
| Si-Bone, INC. | $687.48 | 2022-2024 | |
| Biotronik Nro, INC. | $406.23 | 2025 | Prospera |
| Nalu Medical, INC. | $148.45 | 2025 | Nalu Neurostimulation System |
| Teva Pharmaceuticals USA, INC. | $145.82 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Curonix LLC | $102.63 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $72.27 | 2023-2025 | |
| Axsome Therapeutics, INC. | $54.55 | 2025 | Auvelity |
| Vertos Medical, INC. | $53.54 | 2024 | Mild Device Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $50.93 | 2023-2025 | Belbuca, Xtampza |
| Amgen INC. | $49.31 | 2021-2022 | |
| Almatica Pharma LLC | $33.76 | 2022 | |
| Lundbeck LLC | $30.26 | 2021-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $26.21 | 2021 | |
| Grt US Holding, INC. | $23.00 | 2021 | |
| Fidia Pharma USA INC. | $22.63 | 2024 | Hymovis |
| Bioventus LLC | $17.28 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.41 | 2022 | |
| Stimwave Technologies Incorporated | $15.96 | 2021 | |
| Depuy Synthes Sales INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobie Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.